Muscle Tension Dysphonia Treatment Market Report 2024

This Muscle Tension Dysphonia Treatment market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The muscle tension dysphonia treatment market size has increased by grown steadily in recent years. It will grow from $12.26 billion in 2023 to $12.77 billion in 2024 at a compound annual growth rate (CAGR) of 4.1%. The growth during the historic period can be attributed to heightened awareness of voice therapy, a lack of knowledge about abnormal vocal sounds, a rise in chronic illnesses, an increased risk of benign laryngeal conditions, and growing stress levels among both adults and children.

The muscle tension dysphonia treatment market size is expected to see steady growth in the next few years. It will grow to $15.07 billion in 2028, at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to the rising incidence of voice disorders, increased use of generic medications, higher healthcare expenditure, expanding government-sponsored research and development activities, and a growing demand for personalized diagnostic techniques. Major trends expected during this period include technological advancements, innovations in products, strategic partnerships, investments in research and development, and the adoption of personalized diagnostic approaches.

The increasing prevalence of voice disorders is projected to drive the growth of the muscle tension dysphonia treatment market in the future. Voice disorders encompass conditions that impact the pitch, volume, tone, and quality of a person's voice. The rising incidence of these disorders is attributed to factors such as excessive vocal strain, exposure to loud environments, and the growing need for voice-dependent professions. Treatments for muscle tension dysphonia are effective in managing voice disorders by addressing excessive muscle tension around the larynx through therapies such as voice therapy, physical exercises, and stress management. For example, in March 2024, the National Institutes of Health reported that about 17.9 million U.S. adults aged 18 or older, or 7.6% of the population, experienced voice problems in the past year, with approximately 9.4 million (4%) reporting issues that lasted a week or more. Thus, the increasing prevalence of voice disorders is fueling the growth of the muscle tension dysphonia treatment market.

The growing risk of benign laryngeal conditions is also expected to drive the muscle tension dysphonia treatment market. Benign laryngeal conditions include non-cancerous growths or abnormalities in the larynx, such as nodules or polyps, which can cause symptoms such as hoarseness but are generally non-malignant and have a good prognosis. The risk of these conditions may increase due to factors such as chronic irritation from smoking, vocal strain, and environmental pollutants. Muscle tension dysphonia treatment can help manage benign laryngeal conditions by addressing excessive muscle tension and strain in the larynx that can worsen or mimic issues such as nodules or polyps. For instance, the American Cancer Society estimated in January 2024 that there will be approximately 12,650 new laryngeal cancer cases in 2024, with 10,030 in men and 2,620 in women, and about 3,880 deaths, including 3,120 men and 760 women. The lifetime risk of developing laryngeal cancer is about 1 in 200 for men and 1 in 840 for women. Consequently, the increased risk of benign laryngeal conditions is contributing to the growth of the muscle tension dysphonia treatment market.

Key players in the muscle tension dysphonia treatment market are developing advanced medical solutions, such as medications for cervical dystonia, to improve treatment outcomes and efficacy. Cervical dystonia is a neurological disorder characterized by involuntary muscle contractions in the neck, leading to abnormal movements and postures. For example, in August 2023, Daxxify, a U.S.-based pharmaceutical company, received FDA approval for its first therapeutic use to treat cervical dystonia in adults. This approval was based on phase 3 clinical trials, including ASPEN-1 and ASPEN-OLS. ASPEN-1, which involved 382 participants, met its primary endpoint, demonstrating significant improvement in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) at weeks 4 and 6. The median duration of effect was 20.3 weeks for the high-dose group and 24 weeks for the low-dose group. Common treatment-related side effects included dysphagia, muscular weakness, and injection site pain. In ASPEN-OLS, 357 participants received up to 4 sequential doses of Daxxify, showing improvements in TWSTRS with a median duration of 19.9 to 26 weeks. Common adverse effects in this study included injection site pain, headache, and injection site erythema.

Major companies operating in the muscle tension dysphonia treatment market are Mayo Clinic, Cleveland Clinic, Mount Sinai Health System, Johns Hopkins Medicine, NYU Langone Hospitals, Memorial Sloan Kettering Cancer Center, University of Michigan Health System, UCLA Health, Children's Hospital of Philadelphia, Emory Healthcare, Roswell Park Comprehensive Cancer Center, Freudenberg Medical, St. Jude Children's Research Hospital, The University of California, Massachusetts General Hospital, American Laryngological Association, Synovis Micro Companies Alliance Inc., American Medical Association, Weill Cornell Medicine., Duke University Health System.

North America was the largest region in the muscle tension dysphonia treatment market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the muscle tension dysphonia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the muscle tension dysphonia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Muscle tension dysphonia (MTD) is a voice disorder marked by excessive muscle tension around the larynx during speech. Treatment for MTD generally involves techniques to reduce muscle tension, improve vocal habits, and promote overall vocal health.

The primary treatments for muscle tension dysphonia include medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), proton-pump inhibitors, analgesics, and antacids, as well as voice therapy and behavioral counseling. These medications aim to relieve symptoms or address underlying issues contributing to vocal cord tension and strain. This approach is suitable for various age groups, including children, adults, and the elderly, and addresses causes such as muscle tension and vocal cord damage. These treatments are accessible through various channels, including hospitals, clinics, specialized centers, retail pharmacies, online pharmacies, and drug stores.

The muscle tension dysphonia treatment market research report is one of a series of new reports that provides muscle tension dysphonia treatment market statistics, including muscle tension dysphonia treatment industry global market size, regional shares, competitors with a muscle tension dysphonia treatment market share, detailed muscle tension dysphonia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the muscle tension dysphonia treatment industry. This muscle tension dysphonia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The muscle tension dysphonia treatment market includes revenues earned by entities by providing services such as voice therapy, behavioral modifications, medication management, and patient education. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.